Learn how Pfizer’s focus on immunotherapy aims to help people with multiple myeloma
Pfizer is studying a potential treatment for multiple myeloma that uses a person’s immune system to fight off cancer cells.
We are conducting a series of clinical trials, called the MagnetisMM studies, to evaluate the safety and effectiveness of a study medicine called elranatamab (el-ruh-NAH-tuh-mab).
Elranatamab is given as a subcutaneous injection (a needle inserted under the skin in order to deliver the study medicine). It is thought to work by connecting certain immune system cells, known as T-cells, to myeloma cells. Connecting these cells activates the immune cells to kill the myeloma cells.
The MagnetisMM studies will have their own unique requirements for who may participate (eligibility criteria). The requirements may include your stage of multiple myeloma as well as any previous treatments you may have received.
If you or a loved one are considering participating in these studies, find more information in the clinical trials list below.
Refine your search
8 trials found
These studies will evaluate the safety and effectiveness of a study medicine, called elranatamab, in people with multiple myeloma.
Multiple Myeloma
Multiple Myeloma
Multiple Myeloma
Multiple Myeloma
Multiple Myeloma
Multiple Myeloma
Multiple Myeloma
Relapse Multiple Myeloma, Refractory Multiple Myeloma
Saved trials
Saved trials
You currently don’t have any saved trials. To save a trial, select the bookmark icon on the result listing.
Contact us
For more information about participation in a Pfizer clinical trial, please email or call the Pfizer Clinical Trial Contact Center at 1-800-887-7002.
About multiple myeloma
Plasma cells are produced in healthy bone marrow. Plasma cells are a type of white blood cell that creates antibodies. These antibodies help your body kill germs and fight infection.
Multiple myeloma is a type of blood cancer that forms in bone marrow. Multiple myeloma is when healthy plasma cells change and grow at a rapid pace. Abnormal (myeloma or cancer) plasma cells overcrowd and/or prevent the growth and creation of healthy plasma cells and other cells within the bone marrow.
Like healthy plasma cells, some myeloma cells create antibodies. However, the antibodies don’t work properly, lowering your body’s ability to fight infection. Abnormal plasma cells also build up in the bones and organs, making it difficult for them to work properly, causing issues such as kidney problems.